Trental

Quốc gia: Úc

Ngôn ngữ: Tiếng Anh

Nguồn: Department of Health (Therapeutic Goods Administration)

Thành phần hoạt chất:

Oxpentifylline

Sẵn có từ:

Sanofi-Aventis Australia Pty Ltd

Lớp học:

Medicine Registered

Đặc tính sản phẩm

PRODUCT INFORMATION 
TRENTAL
®
 400 
NAME OF THE DRUG 
NON-PROPRIETARY NAME

Oxpentifylline  
Oxpentifylline and Pentoxifylline are interchangeable and refer to the
same molecule. 
CHEMICAL STRUCTURE 

C
13
H
18
N
4
O
3
      278.3102 
CAS NUMBER 
6493-05-6  
DESCRIPTION 
A trisubstituted xanthine derivative designated chemically as
1-(5-oxohexyl)-3, 7-dimethylxanthine, 
IUPAC name:
3,7-dimethyl-1-(5-oxohexyl)-3.7-dihydro-1H-purine-2,6-dione.
Oxpentifylline is 
soluble in water and ethanol, and sparingly soluble in toluene. 
Trental 400 controlled-release tablets also contain the following
excipients: hydroxyethylcellulose, 
povidone, talc-purified, magnesium stearate, hypromellose, titanium
dioxide, erythrosine, and 
macrogol 8000.  
PHARMACOLOGY 
SITE AND MODE OF ACTION 
It is thought that oxpentifylline and its metabolites improve the
flow properties of blood by 
decreasing its viscosity.  In patients with chronic peripheral
arterial disease, this increases blood 
flow to the affected microcirculation and enhances tissue
oxygenation.  Some of the mechanisms 
by which this is thought to occur
include dose-related haemorrheological effects, such as 
decreased blood viscosity, improved erythrocyte flexibility, decreased
plasma fibrinogen and 
enhanced platelet deaggregation.  However, the precise mode of action
of oxpentifylline and the 
sequence of events leading to clinical improvement are still to be
clearly defined. 
PHARMACOKINETICS 
After oral administration in aqueous solution oxpentifylline is
almost completely absorbed.  It 
undergoes a first-pass effect and the various metabolites appear in
plasma very soon after dosing. 
Peak plasma levels of the parent compound and its metabolites are
reached within 1 hour.  The 
major metabolites are Metabolite I
(1-[5-hydroxy-hexyl]-3,7-dimethylxanthine) and Metabolite V (1-
[3-carboxypropyl]-3,7-dimethylxanthine), and plasma levels of
these metabolites are 5 and 8 times 
greater, respectively,